Topic: Exploring Mechanisms of Resistance and Combination Therapies for Immune Checkpoint Inhibitors
Guest Editor(s)
Guest Editor Assistant(s)
Special Issue Introduction
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but mono-therapy often leads to resistance. To overcome this challenge, the combination of immune checkpoint inhibitors has emerged as a necessary strategy. For primary resistance, combinations of ICIs with chemotherapy have been implemented in lung cancer, breast cancer, and other cases. Despite ongoing research on predictive biomarkers for initial response, there is currently a lack of approved treatments for acquired resistance. Therefore, in-depth investigation into the mechanisms behind acquired resistance and exploration of new combination therapy strategies are crucial to enhancing sustained patient response to ICIs. These efforts hold the potential to significantly improve the overall survival rates of cancer patients.
Proposed topics include, but are not limited to:
1. Mechanisms of resistance to immune checkpoint inhibitors;
2. Combination therapies with immune checkpoint inhibitors to overcome cancer immunotherapy resistance;
3. Multi-omics analysis to identify biomarkers predicting the risk of immunotherapy resistance.
etc.
Proposed topics include, but are not limited to:
1. Mechanisms of resistance to immune checkpoint inhibitors;
2. Combination therapies with immune checkpoint inhibitors to overcome cancer immunotherapy resistance;
3. Multi-omics analysis to identify biomarkers predicting the risk of immunotherapy resistance.
etc.
Submission Deadline
15 Jul 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR240109
Submission Deadline: 15 Jul 2024
Contacts: Louise Pan, Assistant Editor, editorial@cdrjournal.com
